|
1
|
Yerrabothala S, Shaaban H, Capo G,
Maroules M and Debari VA: The impact of diabetes mellitus on breast
cancer outcomes: a single center retrospective study. Pathol Oncol
Res. 20:209–214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee JY, Jeon I, Lee JM, Yoon JM and Park
SM: Diabetes mellitus as an independent risk factor for lung
cancer: a meta-analysis of observational studies. Eur J Cancer.
49:2411–2423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang JY, Chao TT, Lai CC, et al: Risk of
colorectal cancer in type 2 diabetic patients: a population-based
cohort study. Jpn J Clin Oncol. 43:258–263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta SP, Mittal A, Jha DK, Pandeya DR and
Sathian B: Diabetes mellitus and renal cell carcinoma - a hospital
based study from Kathmandu Valley. Asian Pac J Cancer Prev.
13:4963–4965. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Onitilo AA, Stankowski RV, Berg RL, et al:
Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J
Cancer Prev. 23:134–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin CC, Yeh HH, Huang WL, et al: Metformin
enhances cisplatin cytotoxicity by suppressing signal transducer
and activator of transcription-3 activity independently of the
liver kinase B1-AMP-activated protein kinase pathway. Am J Respir
Cell Mol Biol. 49:241–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han D, Li SJ, Zhu YT, Liu L and Li MX:
LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Asian Pac J Cancer Prev. 14:4033–4039. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Quinn BJ, Dallos M, Kitagawa H, et al:
Inhibition of lung tumorigenesis by metformin is associated with
decreased plasma IGF-I and diminished receptor tyrosine kinase
signaling. Cancer Prev Res (Phila). 6:801–810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kourelis TV and Siegel RD: Metformin and
cancer: new applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kato K, Gong J, Iwama H, et al: The
antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Storozhuk Y, Hopmans SN, Sanli T, et al:
Metformin inhibits growth and enhances radiation response of
non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J
Cancer. 108:2021–2032. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kumar S, Meuter A, Thapa P, et al:
Metformin intake is associated with better survival in ovarian
cancer: a case-control study. Cancer. 119:555–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferla R, Haspinger E and Surmacz E:
Metformin inhibits leptin-induced growth and migration of
glioblastoma cells. Oncol Lett. 4:1077–1081. 2012.PubMed/NCBI
|
|
15
|
Kobayashi M, Kato K, Iwama H, et al:
Antitumor effect of metformin in esophageal cancer: In vitro study.
Int J Oncol. 42:517–524. 2013.PubMed/NCBI
|
|
16
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: a
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: a representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mazzone PJ, Rai H, Beukemann M, Xu M, Jain
A and Sasidhar M: The effect of metformin and thiazolidinedione use
on lung cancer in diabetics. BMC Cancer. 12:4102012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ruiter R, Visser LE, van Herk-Sukel MP, et
al: Lower risk of cancer in patients on metformin in comparison
with those on sulfonylurea derivatives: results from a large
population-based follow-up study. Diabetes Care. 35:119–124. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh
DP and Chen CC: Antidiabetes drugs correlate with decreased risk of
lung cancer: a population-based observation in Taiwan. Clin Lung
Cancer. 13:143–148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bodmer M, Becker C, Jick SS and Meier CR:
Metformin does not alter the risk of lung cancer: a case-control
analysis. Lung Cancer. 78:133–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Smiechowski BB, Azoulay L, Yin H, Pollak
MN and Suissa S: The use of metformin and the incidence of lung
cancer in patients with type 2 diabetes. Diabetes Care. 36:124–129.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wells GA, Shea B, O'Connell D, et al: The
Newcastle-Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed.
February 5–2013
|
|
24
|
Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH
and Tseng CH: The influence of type 2 diabetes and glucose-lowering
therapies on cancer risk in the Taiwanese. Exp Diabetes Res.
2012:4137822012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang SY, Chuang CS, Muo CH, et al:
Metformin and the incidence of cancer in patients with diabetes: a
nested case-control study. Diabetes Care. 36:e155–e156. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: a cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Orgel E and Mittelman SD: The links
between insulin resistance, diabetes, and cancer. Curr Diab Rep.
13:213–222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lemke LB, Rogers AB, Nambiar PR and Fox
JG: Obesity and non-insulin-dependent diabetes mellitus in
Swiss-Webster mice associated with late-onset hepatocellular
carcinoma. J Endocrinol. 199:21–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sugiyama T, Nakanishi M, Hoshimoto K, et
al: Severely fluctuating blood glucose levels associated with a
somatostatin-producing ovarian neuroendocrine tumor. J Clin
Endocrinol Metab. 97:3845–3850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pisani P: Hyper-insulinaemia and cancer,
meta-analyses of epidemiological studies. Arch Physiol Biochem.
114:63–70. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thakkar B, Aronis KN, Vamvini MT, Shields
K and Mantzoros CS: Metformin and sulfonylureas in relation to
cancer risk in type II diabetes patients: a meta-analysis using
primary data of published studies. Metabolism. 62:922–934. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang CH, Lin JW, Wu LC, Lai MS and Chuang
LM: Oral insulin secretagogues, insulin, and cancer risk in type 2
diabetes mellitus. J Clin Endocrinol Metab. 97:E1170–E1175. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kao CH, Sun LM, Chen PC, et al: A
population-based cohort study in Taiwan - use of insulin
sensitizers can decrease cancer risk in diabetic patients? Ann
Oncol. 24:523–530. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Colmers IN, Bowker SL and Johnson JA:
Thiazolidinedione use and cancer incidence in type 2 diabetes: a
systematic review and meta-analysis. Diabetes Metab. 38:475–484.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Staa TP, Patel D, Gallagher AM and de
Bruin ML: Glucose-lowering agents and the patterns of risk for
cancer: a study with the General Practice Research Database and
secondary care data. Diabetologia. 55:654–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
